Brolucizumab as Good as Aflibercept for Neovascular AMD

Brolucizumab is noninferior to aflibercept and requires less-frequent injections for patients with neovascular age-related macular degeneration (nAMD), according to results from two phase-3 trials.
Reuters Health Information

Full Story →